Afrezza® INHALE-1 Study in Pediatrics
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT04974528
- Lead Sponsor
- Mannkind Corporation
- Brief Summary
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog \[RAA\] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all subjects will enter a treatment extension where subjects will receive Afrezza until Week 52. The purpose of the treatment extension is to assess safety and efficacy with continued use of Afrezza.
Pediatric subjects ≥4 and \<18 years of age will be enrolled in this study. Subjects will be randomly assigned in a 1:1 ratio to either the Afrezza group or the RAA injection group.
The study is composed of:
* Up to 5-week screening/run-in period
* 26 week randomized treatment period
* 26-week treatment extension
* 4-week follow-up period
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 319
- Assent from the pediatric subject, as appropriate, and fully informed consent from the parent(s) or legal guardian, as required by both state and federal laws and the local Institutional Review Board (IRB)
- Subjects ≥4 and <18 years of age
- Clinical diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) per the Investigator and have been using insulin for at least 6 months for T1DM, or at least 3 months for T2DM
- Treatment with basal-bolus insulin therapy delivered by multiple daily injections for at least 2 weeks
- Bolus insulins are restricted to the RAAs insulin lispro, insulin aspart or insulin glulisine, including biosimilar products
- Basal insulins are restricted to insulin glargine, insulin degludec or insulin detemir, including biosimilar products
- Access to stable WiFi connection
- HbA1c ≥7.0% and ≤11%
- Average prandial dose of insulin ≥2 units per meal
- Utilized CGM for ≥70% of the time over a consecutive 14-day period preceding randomization
- History of recent blood transfusions (within previous 3 months), hemoglobinopathies, or any other conditions that affect HbA1c measurements
- Recent history of asthma (defined as using any medications to treat within the last year), any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease
- History of serious complications of diabetes (e.g., active proliferative retinopathy or symptomatic autonomic neuropathy), or likely need for specific treatment for diabetic retinopathy (laser photocoagulation, vitrectomy, other) in the next year
- FEV1 and FEV1/forced vital capacity (FVC) ≤80% of predicted Global Lung Function Initiative (GLI) value
- Inability to achieve an acceptable FEV1 and FVC reading for subjects ≥8 years of age would make the subject ineligible
- For subjects <8 years of age who are unable to achieve an acceptable FVC reading, FEV1 only may be assessed; inability to achieve an acceptable FEV1 would make the subject ineligible
- Respiratory tract infection within 14 days before screening (subject may return 14 days after resolution of symptoms for rescreening)
- Inability or unwillingness to perform study procedures
- Exposure to any investigational product(s), including drugs or devices, in the past 30 days
- Any disease other than diabetes or exposure to any medication that, in the judgment of the Investigator, may impact glucose metabolism and current or anticipated acute uses of glucocorticoids or weight loss medications, with the exception of metformin and/or GLP-1 agonists (if GLP-1 agonists used for at least the 3 months prior to enrollment) in subjects with T2DM
- Use of antiadrenergic drugs (e.g., clonidine)
- Any concurrent illness (other than diabetes mellitus) not controlled by a stable therapeutic regimen
- Current uncontrolled eating disorder (e.g., anorexia or bulimia nervosa)
- Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the Investigator or the Sponsor, would make the subject an unsuitable candidate for participation in the study
- Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) for the preceding 6 months and/or positive urine cotinine test
- Female subject who is pregnant, breast-feeding, intends to become pregnant, or is of child-bearing potential, sexually active and not using adequate contraceptive methods as required by local regulation or practice
- An event of severe hypoglycemia, as judged by the Investigator, within the last 90 days prior to screening
- An episode of DKA requiring hospitalization within the last 90 days prior to screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description RAA Injection + Basal Insulin Rapid-acting Insulin Analog Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient. RAA Injection + Basal Insulin Basal Insulin Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient. Afrezza (Technosphere Insulin) + Basal Insulin Basal Insulin Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient. Afrezza (Technosphere Insulin) + Basal Insulin Afrezza Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.
- Primary Outcome Measures
Name Time Method Change in HbA1c 26 weeks Change in HbA1c from baseline to Week 26, for noninferiority assessment
- Secondary Outcome Measures
Name Time Method Event rate of pooled level 2 and level 3 hypoglycemia 26 weeks Event rate of pooled level 2 and level 3 hypoglycemia (SMBG \< 54 mg/dL and/or severe hypoglycemic events reported on the adverse event CRF) during the 26 -week randomized treatment period, for superiority assessment.
Change in HbA1c 26 weeks Change in HbA1c from baseline to Week 26, for superiority assessment
Change in Fasting Plasma Glucose (FPG) 26 weeks Change in FPG from baseline to Week 26, for superiority assessment
Trial Locations
- Locations (39)
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
Rocky Mountain Clinical Research
🇺🇸Idaho Falls, Idaho, United States
Joe DiMaggio Children's Hospital
🇺🇸Hollywood, Florida, United States
Nemours Children's Hospital, Delaware
🇺🇸Wilmington, Delaware, United States
Iowa Diabetes Research, IDR
🇺🇸West Des Moines, Iowa, United States
Emory University, Children's Healthcare of Atlanta
🇺🇸Atlanta, Georgia, United States
AM Diabetes and Endocrinology Center
🇺🇸Bartlett, Tennessee, United States
NYU Langone, Hassenfeld Children's Hospital
🇺🇸New York, New York, United States
DHR Health
🇺🇸Edinburg, Texas, United States
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Seattle Children's
🇺🇸Seattle, Washington, United States
Dr. Barry J. Reiner
🇺🇸Baltimore, Maryland, United States
The DOCS
🇺🇸Las Vegas, Nevada, United States
Cincinnati Children's Hospital
🇺🇸Cincinnati, Ohio, United States
University of California San Francisco
🇺🇸San Francisco, California, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Diabetes & Glandular Disease Clinic, DGD
🇺🇸San Antonio, Texas, United States
Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States
Children's Hospital of Orange County
🇺🇸Orange, California, United States
Joslin Diabetes Center
🇺🇸Boston, Massachusetts, United States
UBMD Pediatrics Buffalo
🇺🇸Buffalo, New York, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
UT Southwestern
🇺🇸Dallas, Texas, United States
University of California San Diego, Rady Children's Hospital
🇺🇸San Diego, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
Michigan Pediatric Endocrine and Diabetes Services
🇺🇸Livonia, Michigan, United States
Atlantic Health
🇺🇸Morristown, New Jersey, United States
University of South Florida
🇺🇸Tampa, Florida, United States
University of Louisville, Norton Children's Hospital
🇺🇸Louisville, Kentucky, United States
Yale New Haven Hospital
🇺🇸New Haven, Connecticut, United States
Sutter Institute for Medical Research (formerly Center of Excellence in Diabetes and Endocrinology)
🇺🇸Sacramento, California, United States
Advent Health Orlando
🇺🇸Orlando, Florida, United States
Children's Mercy Hospital
🇺🇸Kansas City, Missouri, United States
Oklahoma Children's Hospital
🇺🇸Oklahoma City, Oklahoma, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
University of Florida
🇺🇸Gainesville, Florida, United States
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States